Endoscopic Ultrasound-Guided Fine-Needle Biopsy Versus Aspiration for Tissue Sampling Adequacy for Molecular Testing in Pancreatic Ductal Adenocarcinoma
Cancers · 12.02.2024 · 16 (4) · 761
DOI: 10.3390/cancers16040761 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 12.02.2024. Verfasst von Wael T Mohamed und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transplant Hepatology, Cleveland Clinic, Cleveland, OH 44114, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aims: There is limited literature on sample adequacy for molecular testing in pancreatic ductal adenocarcinoma obtained via endoscopic ultrasound (EUS) fine-needle aspiration (FNA) versus EUS fine-needle biopsy (FNB). We aimed to compare these two modalities regarding sample adequacy for molecular and genomic sequencing.
Methods
We reviewed all patients with pancreatic ductal adenocarcinoma who underwent EUS at Saint Luke’s Hospital from 2018 to 2021. The patients were categorized based on the method of EUS tissue acquisition, specifically FNA or FNB. A comprehensive evaluation was conducted for all cases by cytotechnologists.
Results
Out of 132 patients who underwent EUS-guided biopsies, 76 opted for FNA, 48 opted for FNB, and 8 opted for a combination of both. The average number of passes required for FNB and FNA was 2.58 ± 1.06 and 2.49 ± 1.07, respectively (p = 0.704), indicating no significant difference. Interestingly, 71.4% (35) of FNB-obtained samples were deemed adequate for molecular testing, surpassing the 32.1% (26) adequacy observed with FNA (p < 0.001). Additionally, 46.4% (26) of FNB-obtained samples were considered adequate for genomic testing, a notable improvement over the 23.8% (20) adequacy observed with FNA (p = 0.005).
Conclusion
Although the number of passes required for cytologic diagnosis did not differ significantly between EUS-FNB and EUS-FNA, the former demonstrated superiority in obtaining samples adequate for molecular testing. Tumor surface area and cellularity were crucial parameters in determining sample adequacy for molecular testing, irrespective of the chosen tissue acquisition modality.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Transplant Hepatology, Cleveland Clinic, Cleveland, OH 44114, USA.
- Department of Internal Medicine, University of Missouri-Kansas City, Kansas City, MO 64108, USA.
- Department of Gastroenterology, University of Missouri-Kansas City, Kansas City, MO 64108, USA.
- Department of Cardiovascular Research, Saint Luke's Health System, Kansas City, MO 64108, USA.
- Department of Pathology, University of Missouri-Kansas City, Kansas City, MO 64108, USA.
- MAWD Pathology Group, Lenexa, KS 66215, USA.
ORCID-Profile: Wael T Mohamed, Vinay Jahagirdar, Fouad Jaber, Zhuxuan Fu, Ossama W Tawfik
Zitieren
APA
Mohamed, W. T., Jahagirdar, V., Jaber, F., Ahmed, M. K., Fatima, I., Bierman, T., Fu, Z., Jones, P. G., Hassan, A. F., Faber, E., Clarkston, W. K., Ghoz, H., Tawfik, O. W., & Jonnalagadda, S. (2024). Endoscopic Ultrasound-Guided Fine-Needle Biopsy Versus Aspiration for Tissue Sampling Adequacy for Molecular Testing in Pancreatic Ductal Adenocarcinoma. Cancers, 16(4), 761. https://doi.org/10.3390/cancers16040761
Vancouver
Mohamed WT, Jahagirdar V, Jaber F, Ahmed MK, Fatima I, Bierman T, et al. Endoscopic Ultrasound-Guided Fine-Needle Biopsy Versus Aspiration for Tissue Sampling Adequacy for Molecular Testing in Pancreatic Ductal Adenocarcinoma. Cancers. 2024;16(4):761. doi:10.3390/cancers16040761
BibTeX
@article{Mohamed2024,
author = {Mohamed, Wael T and Jahagirdar, Vinay and Jaber, Fouad and Ahmed, Mohamed K and Fatima, Ifrah and Bierman, Thomas and Fu, Zhuxuan and Jones, Philip G and Hassan, Amira F and Faber, Erin and Clarkston, Wendell K and Ghoz, Hassan and Tawfik, Ossama W and Jonnalagadda, Sreeni},
title = {Endoscopic Ultrasound-Guided Fine-Needle Biopsy Versus Aspiration for Tissue Sampling Adequacy for Molecular Testing in Pancreatic Ductal Adenocarcinoma},
journal = {Cancers},
year = {2024},
volume = {16},
number = {4},
pages = {761},
doi = {10.3390/cancers16040761}
}
EUVIMED